Princeton, New Jersey, November 10, 2014 – Sandoz today announced the US market introduction of cyclophosphamide injection, USP.
Sandoz is launching cyclophosphamide injection, USP, through collaboration with Jiangsu Hengrui Medicine Co., the owner of the product’s Abbreviated New Drug Application (ANDA).
Cyclophosphamide for injection, USP, is a chemotherapy agent used to treat certain types of cancer in adults and pediatric patients. It is also used in selected cases of biopsy proven “minimal change” nephrotic syndrome in children. New cases of leukemia, lymphoma and myeloma are expected to account for 9.4 percent of the estimated 1,665,540 new cancer cases diagnosed in the US in 2014.1
“We are pleased to add cyclophosphamide injection to our strong and growing portfolio of generic oncology injectables,” said Peter Goldschmidt, President of Sandoz Inc. “Collaborations with pharmaceutical companies are an important aspect of our strategy of being first-to-market with key affordable, high-quality treatment options.”
According to IMS Health, aggregate US sales for cyclophosphamide injection were approximately USD 420 million for the 12 months ending in September 2014. Sandoz will market cyclophosphamide 500mg, 1g, and 2g single-dose vials.